Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis. | 2021 | Journal of Vascular Surgery: Venous and Lymphatic Disorders |
Drug-drug interactions leading to adverse drug reactions with rivaroxaban: a systematic review of the literature and analysis of VigiBase. | 2021 | Journal of Personalized Medicine |
A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: a meta-analysis. | 2020 | Journal of Orthopaedic Surgery |
A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation. | 2020 | Clinical and Applied Thrombosis/Hemostasis |
The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis. | 2020 | American Journal of Cardiovascular Drugs |
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis. | 2020 | Thrombosis Research |
Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement. | 2020 | JAMA |
Economic evaluation of rivaroxaban versus enoxaparin for prevention of venous thromboembolism after total knee replacement and total hip replacement: a systematic review. | 2020 | Clinical Drug Investigation |
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. | 2020 | Journal of Thrombosis and Thrombolysis |
Efficacy and safety of non-vitamin K anticoagulants for atrial fibrillation in relation to different renal function levels: a network meta-analysis. | 2020 | Cardiovascular Therapeutics |
Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation. | 2020 | Circulation: Cardiovascular Quality and Outcomes |
Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. | 2020 | Frontiers in Medicine |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. | 2020 | Cochrane Database of Systematic Reviews |
Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: a systematic review and meta-analysis. | 2019 | Medicine |
Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. | 2019 | Blood Advances |
Rivaroxaban versus aspirin in prevention of venous thromboembolism: a meta-analysis of 9 randomized controlled trials comprising 7,656 patients. | 2019 | Stroke, Systemic or Venous Thromboembolism |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. | 2019 | Nephrology Dialysis Transplantation |
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis. | 2019 | Journal of Thrombosis and Thrombolysis |
Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. | 2019 | Heart |
Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. | 2019 | The Lancet Haematology |
Venous thromboembolism prophylaxis strategies for people undergoing elective total hip replacement: a systematic review and network meta-analysis. | 2019 | Value in Health |
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation – a network meta-analysis of real-world data. | 2019 | VASA |
Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty. | 2018 | Medicine |
Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. | 2018 | The American Journal of Cardiology |
Treatment for superficial thrombophlebitis of the leg. | 2018 | Cochrane Database of Systematic Reviews |
Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. | 2018 | Pharamacotherapy |
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. | 2017 | BMJ |
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. | 2017 | Current Medical Research and Opinion |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. | 2017 | Clinical Therapeutics |
Effects of non–vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. | 2017 | Journal of the American Heart Association |
Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. | 2017 | The Journal of Arthroplasty |
Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. | 2017 | Acta Orthopaedica |
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. | 2017 | Cochrane Database of Systematic Reviews |
Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. | 2017 | Stroke |
Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. | 2016 | PLoS One |